Market Analysis:
Actinic keratosis, simply put,
is a scaly, rough patch on the skin which results from years of sun exposure.
It is commonly found on the neck, scalp, forearms, back of the hands, ears,
lips, or face. The size varies from a small inch to about a diameter, and when
left untreated, such areas of the skin can turn into a serious type of skin
cancer. Change in the color of the skin (brown, flesh-colored, or pink), hard
wart-like surface, burning sensation and itching, and rough, patchy, scaly skin
are some of its common symptoms.
The global Actinic
Keratosis Treatment Market is predicted to touch USD 6,088.4 million
at a 4.20% CAGR over the forecast period (2015-2024),
states the new Market Research Future (MRFR) report. No two cases will appear
the same, yet is likely to share similar features such as sandpaper texture,
crusty patches, raised patches, and red scales. Though anyone can develop
actinic keratosis, but those with fair skin, particularly blonde or red hair,
green or blue eyes, or skin that easily burns or freckles have a higher risk of
experiencing actinic keratosis.
Various factors are propelling
the actinic keratosis treatment market growth. These factors, according to the
new MRFR report, include its increasing prevalence, increasing acceptance of
therapeutic procedures that are minimally invasive, growing geriatric
population, and the presence of suitable medical coverage. Additional factors
pushing market growth include the availability of suitable medical attention
and environmental factors such as excessive sun exposure and ozone
depletion.
On the flip side, high cost of
treatment, risk factors related to the available treatment, low penetration of
actinic keratosis treatment market especially in developing economies, and
scarcity of skilled medical professionals are factors that may impede the
actinic keratosis treatment market growth over the forecast period.
Key Players:
·
Cipher Pharmaceuticals Inc.
·
Valeant Pharmaceuticals
·
Sun Pharmaceutical Industries
Ltd
·
Alma Lasers
·
Stanford Chemicals
·
3M
·
Leo Pharma
·
BioLineRx
·
Biofrontera AG
Market Segmentation:
·
The MRFR report provides a
complete segmental analysis of the actinic keratosis treatment market report on
the basis of end user, procedure, and medication.
·
Based on medication, the actinic
keratosis treatment market is segmented into diclofenac gel, ingenol mebutate
gel, imiquimod cream, fluorouracil cream, and others.
·
Based on procedure, the actinic
keratosis treatment market is segmented into chemical peels, laser,
photodynamic therapy, cryotherapy, and others. Of these, the cryotherapy
segment will have the largest share in the market over the forecast period.
This is a common treatment used for actinic keratosis.
·
Based on end user, the actinic
keratosis treatment is segmented into ambulatory surgical centers, dermatology
clinics, and hospitals and oncology centers. Of these, the hospitals and
oncology segment will dominate the market over the forecast period.
Regional Analysis:
By region, the actinic keratosis
treatment market report covers the latest trends and growth opportunities
across the Asia Pacific, Europe, the Americas, and the Middle East and Africa.
Of these, the Americas will spearhead the market over the forecast period.
Factors aiding growth in the region include easy availability of advanced
treatment methods such as monotherapy and combination therapy and increasing
efforts taken on cancer research in the region.
The actinic keratosis treatment
market in the APAC region is predicted to have significant growth over the
forecast period. Factors aiding growth in the region include growing government
support for medical tourism, rising healthcare spending, rising literacy rates,
rapidly growing healthcare infrastructure, and rising disposable income. India,
Japan, and China are the key contributors in this region.
The actinic keratosis treatment
market in Europe will have a favorable growth over the forecast period while
the Middle East and Africa will experience sluggish growth.
No comments:
Post a Comment